Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Study sponsor: Kura Oncology, Inc. · KURA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-03-31Actual
Enrollment · participants65Actual
Source updated2024-06-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.